Year Later, Indian Import Duties Still In Place On Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Import duties still in place in India on the most promising cancer drugs are keeping the price to Indians at about 35 percent more than prices charged elsewhere in the world. The import duties were to have been lifted early last year on certain life-saving drugs, but red tape apparently has delayed the exemptions. A Finance Ministry official said the agency still had not received a recommendation from the Health Ministry for drugs to be placed on a list of exempted drugs. The government had listed 14 cancer drugs that were supposed to be exempt from countervailing duties and have import duties reduced to 5 percent. (Click here for more
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.